The 4-Aminomethylphenoxy-Benzoxaborole AN3057 as a Potential Treatment Option for Primary Amoebic Meningoencephalitis

Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0150622. doi: 10.1128/aac.01506-22. Epub 2023 Jan 23.

Abstract

Primary amoebic meningoencephalitis is a rare but fatal central nervous system (CNS) disease caused by the "brain-eating amoeba" Naegleria fowleri. A major obstacle is the requirement for drugs with the ability to cross the blood-brain barrier, which are used in extremely high doses, cause severe side effects, and are usually ineffective. We discovered that the 4-aminomethylphenoxy-benzoxaborole AN3057 exhibits nanomolar potency against N. fowleri, and experimental treatment of infected mice significantly prolonged survival and demonstrated a 28% relapse-free cure rate.

Keywords: Naegleria fowleri; amoeba; antiparasitic; oxaborole; primary amoebic meningoencephalitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amebiasis* / drug therapy
  • Animals
  • Blood-Brain Barrier
  • Central Nervous System Protozoal Infections* / drug therapy
  • Meningoencephalitis*
  • Mice
  • Naegleria fowleri*